vs
Prestige Consumer Healthcare Inc.（PBH）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Prestige Consumer Healthcare Inc.的1.3倍（$362.7M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs -10.7%，领先27.1%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $-193.1M），过去两年世纪互联的营收复合增速更高（17.4% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
PBH vs VNET — 直观对比
营收规模更大
VNET
是对方的1.3倍
$283.4M
净利率更高
PBH
高出27.1%
-10.7%
自由现金流更多
PBH
多$268.3M
$-193.1M
两年增速更快
VNET
近两年复合增速
1.2%
损益表 — Q3 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $362.7M |
| 净利润 | $46.7M | $-38.7M |
| 毛利率 | 55.5% | 20.9% |
| 营业利润率 | 29.1% | 0.5% |
| 净利率 | 16.5% | -10.7% |
| 营收同比 | -2.4% | — |
| 净利润同比 | -23.5% | — |
| 每股收益（稀释后） | $0.97 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBHVNET
| Q4 25 | $283.4M | — | ||
| Q3 25 | $274.1M | $362.7M | ||
| Q2 25 | $249.5M | — | ||
| Q1 25 | $296.5M | $309.5M | ||
| Q4 24 | $290.3M | — | ||
| Q3 24 | $283.8M | $302.2M | ||
| Q2 24 | $267.1M | $274.4M | ||
| Q1 24 | $277.0M | $262.9M |
净利润PBHVNET
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | $-38.7M | ||
| Q2 25 | $47.5M | — | ||
| Q1 25 | $50.1M | $-2.4M | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $54.4M | $-2.1M | ||
| Q2 24 | $49.1M | $-1.1M | ||
| Q1 24 | $49.5M | $-22.0M |
毛利率PBHVNET
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | 20.9% | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | 25.2% | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | 23.2% | ||
| Q2 24 | 54.7% | 21.3% | ||
| Q1 24 | 54.8% | 21.6% |
营业利润率PBHVNET
| Q4 25 | 29.1% | — | ||
| Q3 25 | 29.1% | 0.5% | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 29.8% | 0.1% | ||
| Q4 24 | 31.7% | — | ||
| Q3 24 | 29.7% | 24.5% | ||
| Q2 24 | 27.0% | 0.2% | ||
| Q1 24 | 29.7% | 0.2% |
净利率PBHVNET
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | -10.7% | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 16.9% | -0.8% | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 19.2% | -0.7% | ||
| Q2 24 | 18.4% | -0.4% | ||
| Q1 24 | 17.9% | -8.4% |
每股收益（稀释后）PBHVNET
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.86 | — | ||
| Q2 25 | $0.95 | — | ||
| Q1 25 | $1.00 | — | ||
| Q4 24 | $1.22 | — | ||
| Q3 24 | $1.09 | — | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.98 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $492.1M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $890.8M |
| 总资产 | $3.5B | $6.1B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
现金及短期投资PBHVNET
| Q4 25 | $62.4M | — | ||
| Q3 25 | $119.1M | $492.1M | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $97.9M | $544.3M | ||
| Q4 24 | $50.9M | — | ||
| Q3 24 | $51.5M | $219.5M | ||
| Q2 24 | $34.3M | $247.2M | ||
| Q1 24 | $46.5M | $246.9M |
总债务PBHVNET
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
股东权益PBHVNET
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | $890.8M | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.8B | $927.8M | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.7B | $902.9M | ||
| Q2 24 | $1.7B | $900.6M | ||
| Q1 24 | $1.7B | $895.1M |
总资产PBHVNET
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.4B | $6.1B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.4B | $5.4B | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.3B | $4.3B | ||
| Q2 24 | $3.3B | $4.0B | ||
| Q1 24 | $3.3B | $3.9B |
负债/权益比PBHVNET
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | 1.28× | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $-193.1M |
| 自由现金流率自由现金流/营收 | 26.6% | -53.2% |
| 资本支出强度资本支出/营收 | 1.1% | 84.6% |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流PBHVNET
| Q4 25 | $78.3M | — | ||
| Q3 25 | $57.5M | $113.8M | ||
| Q2 25 | $79.0M | — | ||
| Q1 25 | $61.8M | $27.0M | ||
| Q4 24 | $65.1M | — | ||
| Q3 24 | $69.8M | $108.3M | ||
| Q2 24 | $54.8M | $55.8M | ||
| Q1 24 | $66.9M | $37.1M |
自由现金流PBHVNET
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | $-193.1M | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | $-220.0M | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | $-95.0M | ||
| Q2 24 | $53.6M | $-81.6M | ||
| Q1 24 | $63.8M | $-102.2M |
自由现金流率PBHVNET
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | -53.2% | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | -71.1% | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | -31.4% | ||
| Q2 24 | 20.1% | -29.8% | ||
| Q1 24 | 23.0% | -38.9% |
资本支出强度PBHVNET
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | 84.6% | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | 79.8% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | 67.3% | ||
| Q2 24 | 0.4% | 50.1% | ||
| Q1 24 | 1.1% | 53.0% |
现金转化率PBHVNET
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
VNET
暂无分部数据
